This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Competent National Authority:National Biodiversity Authority ()5th Floor, TICEL Biopark, CSIR Road, TaramaniChennai, Tamilnadu
600 113, IndiaPhone: +91 44 2254 2777,Fax: +91 44 2254 1200,Website: http://www.nbaindia.org,
Application in Form-III for seeking approval for the invention Novel highly bioavailable, water soluble, sustained release Nano formulation of hydrophobic plant derived compounds and extracts for obtaining IP Rights in India, USA, Malaysia, Australia, Philippines, Brazil, Indonesia and Europe
Indian Patent Application Number: 2019/CHE/2012
Person:Dr Ttimurtulu GolakotiSenior Vice President,Phone: +91 866-2545447,Fax:Email: mail@lailanutra.in,Website:Related OrganizationM/s Laila Pharmaceuticals Pvt Ltd (LPPL)Private sector (business and industry)40-15-15, Brindavan Colony, LabbipetVijayawada, Andra Pradesh
520 010, IndiaPhone: +91 866-2545447,Fax:Email: info@lailapharma.com,Website:
Organization:M/s Laila Pharmaceuticals Pvt Ltd (LPPL)Private sector (business and industry)40-15-15, Brindavan Colony, LabbipetVijayawada, Andra Pradesh
520 010, IndiaPhone: +91 866-2545447,Fax:Email: info@lailapharma.com,Website:
1. The user shall notify the NBA within 60 days from the date of grant of IPR and also assignment or licence of the IPR to any person, if any
2. If the user himself commercializes the process/product/innovation, the monetary sharing shall be 0.2% on the annual gross ex-factory sale minus government taxes.
3. The user needs to inform the NBA about any commercialization made on the IP Rights granted within 45 days from the date of such event.
4. The user shall submit annual report to NBA as per the terms and conditions agreed upon.
1. If the user assigns/licenses the process/product/innovation to a third party for commercialization, the user shall pay to NBA 3.0% of the fee received (in any form including the license / assignee fee) and 2.0% of the royalty amount received annually from the assignee/licensee.
2. In case the user assigns or transfer the IPR to any person, the user undertakes to attach this agreement as an appendix to the assignment instrument which shall be binding upon such person.
| Unique identifier | Status | Date |
|---|---|---|
| ABSCH-IRCC-IN-240670-1 |
REVOKED
OLD VERSION
PUBLISHED
DELETED
|
Sujata Arora (sujata@nic.in)
10 Aug 2018 08:28 on 10 Aug 2018 08:28
|
